We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Astellas Pharma Inc (PK) | USOTC:ALPMY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.025 | -0.25% | 9.90 | 9.75 | 9.98 | 9.90 | 9.85 | 9.85 | 259,604 | 21:03:49 |
From May 2021 to May 2024
By Isaac Taylor
Astellas Pharma Inc. and Seagen Inc. announced Wednesday that the European Commission has approved a monotherapy for the treatment of adult patients with locally advanced or metastatic urothelial cancer.
The approval is for patients who have previously received a platinum-containing chemotherapy and a PD-1/L1 inhibitor.
Urothelial cancer is the most common type of bladder cancer, comprising 90% of cases. Globally, roughly 573,000 new cases of bladder cancer and 212,000 deaths are reported annually.
The EC approval is supported by data from a global phase three trial that showed an overall survival benefit compared with chemotherapy.
Write to Isaac Taylor at isaac.taylor@wsj.com
(END) Dow Jones Newswires
April 13, 2022 12:16 ET (16:16 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Astellas Pharma (PK) Chart |
1 Month Astellas Pharma (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
